NAEOTOM Alpha.Peak/ NAEOTOM Alpha; NAEOTOM Alpha.Pro; NAEOTOM Alpha.Prime

The Siemens NAEOTOM Alpha series of computed tomography (CT) X-ray systems, featuring advanced photon-counting detector technology, has been deemed substantially equivalent to legally marketed devices, allowing for their market entry. This regulatory approval is based on extensive non-clinical testing demonstrating their safety, effectiveness, and comparable performance for diverse applications including diagnosis, treatment planning, and low-dose lung cancer screening, enhanced by the SOMARIS/10 syngo CT VB20 software.

A determination has been made that several computed tomography (CT) X-ray systems, specifically the NAEOTOM Alpha.Peak, NAEOTOM Alpha, NAEOTOM Alpha.Pro, and NAEOTOM Alpha.Prime, from Siemens Medical Solutions USA, Inc., are substantially equivalent to legally marketed systems. This decision allows the manufacturer to market these devices, provided they comply with applicable general controls provisions and other federal regulations, including requirements for annual registration, device listing, good manufacturing practice, and labeling. These advanced CT systems utilize photon-counting detector technology and are intended to generate cross-sectional images that aid in diagnosis, treatment, and radiation therapy planning, as well as for diagnostic and therapeutic interventions, including low-dose lung cancer screening. The updated systems introduce new models and an enhanced software version, SOMARIS/10 syngo CT VB20, which expands support for radiotherapy planning. Extensive non-clinical testing, verification, and validation were conducted, demonstrating the safety and effectiveness of the updated systems and their comparable performance to previously available counterparts, with specific considerations for cybersecurity and wireless coexistence.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific improvements does the photon-counting detector technology in the NAEOTOM Alpha systems offer in terms of image quality or dose reduction compared to conventional CT scanners for different clinical applications?; How does the SOMARIS/10 syngo CT VB20 software specifically enhance radiotherapy planning capabilities and workflow compared to previous software versions or alternative systems?; Can more detailed information be provided on the non-clinical testing protocols and results that demonstrated the safety, effectiveness, and comparable performance of these updated CT systems?; What specific cybersecurity measures have been implemented in the NAEOTOM Alpha systems to protect patient data and ensure system integrity in a hospital network environment?; What are the long-term clinical outcomes or economic impacts anticipated from the widespread adoption of these systems for low-dose lung cancer screening?